A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an ...

All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is ...

Patent cliffs and falling R&D productivity push the biggest players toward other people's science – our report puts numbers ...

Monte Rosa’s NEK7-targeting drug pulled several heart-risk biomarkers toward healthy levels in 108 people with obesity.

QIMA Life Sciences launches SQINGEVITY, bringing biological testing and clinical studies together to examine claims about ...

Mighty Therapeutics and the University of Washington will use pilot data on elamipretide to design a larger trial in older ...

Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

A Lancet Neurology study of 130 blood proteins in patients receiving lecanemab suggests amyloid clearance and cognitive ...

Aged beagle data hint at lower biological age and preliminary muscle changes with SIRT6c treatment, although key readouts ...

MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.

Arvinas presented early biomarker data on ARV-102, an oral drug built to clear the LRRK2 protein, at a major Parkinson’s ...

Lovehoney’s hormone-free MenoPulse device launches, pairing air-pulse tech with early data on symptoms and autonomic function ...